Quantib wins FDA clearance for prostate MRI AI software

2020 10 21 01 09 2843 2020 10 21 Quantib 400

Artificial intelligence (AI) software developer Quantib has garnered U.S. Food and Drug Administration (FDA) clearance for an AI application designed to assist radiologists in interpreting prostate MRI exams.

The zero-footprint software features a suite of tools, including an image-based calculation of prostate-specific antigen density that's automatically incorporated into the final report, according to the vendor. The application is the sixth from Quantib to receive FDA clearance.

Quantib's prostate AI software features a suite of tools aimed at improving radiologist performance in assessing prostate MRI exams.Quantib's prostate AI software features a suite of tools aimed at improving radiologist performance in assessing prostate MRI exams.

It also provides a biparametric heat map representation that highlights suspicious areas for radiologists. What's more, the software enables assessment of regions of interests and determination of the PI-RADS score, while also standardizing reporting, Quantib said.

The firm said it plans to deploy the software in 10 facilities this year; a waitlist will be opened for 2021. Enhanced features are also being developed and will be made available on the software over the coming months, according to Quantib.

Page 1 of 605
Next Page